1[1]Bagyley BC,Kerr DJ.Anticancer drug development[M].San Diego:Academic Press,2002.31 被引量:1
2[2]Levitzki A,Gazit A.Tyrosine kinase inhibition:an approach to drug development[J].Science,1995,267(5205):1782 被引量:1
3[3]Shawver LK,Slamon D,Ullrich A.Smart drugs:Tyrosine kinase inhibitors in cancer therapy[J].Cancer cell,2002,1(2):117 被引量:1
4[4]Klapper LN,Kirschbaum MH,Sela M,et al.Biochemical and clinical implications of the ErbB/HER signaling network of growth actor receptors[J].Adv Cancer Res,2000,77(1):25 被引量:1
6[6]Su SJ,Lai MD,Yeh TM,et al.Overexpression of HER22/neu enhances the sensitivity of human bladder cancer cells to urinary isfavones[J].Eur J Cancer,2001,37(11):1413 被引量:1
8[8]Farivar RS,Gardner-Thorpe J,Ito H,et al.The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines[J].J Surg Res,2003,115(2):219 被引量:1
9[9]EL-Zarruk AA,van den berg HW.The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors(EGFR)and the inhibition of EGFR tyrosine kinase[J].Cancer Lett,1999,142(2):185 被引量:1
10[10]Mu F,Coffing SL,Riese DJ,et al.Design,synthesis,and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases,as well as tubulin polymerization[J].J Med Chem.2001,44(3):441 被引量:1